nivolumab + relatlimab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
nivolumab + relatlimab: clinical details
Prescribing considerations
- Initiate and supervise treatment within an experienced oncology service; issue and explain the patient card.
- Assess carefully in pre-existing autoimmune disease, previous myocarditis, active or untreated brain or leptomeningeal metastases, poor performance status, or a need for baseline systemic immunosuppression because combination-specific evidence is limited.
- Balance benefit against the risks of solid-organ rejection or severe graft-versus-host disease in transplant recipients.
- Use caution in severe renal or hepatic impairment because available data are limited.
- Investigate suspected immune toxicity promptly, exclude infection or disease progression, and follow product-specific interruption, discontinuation and immunosuppression guidance.
Contraindications and cautions
- Hypersensitivity to nivolumab, relatlimab or any excipient.
Monitoring
- Assess for immune-related toxicity affecting the lungs, bowel, liver, kidneys, skin, heart, nervous system, muscles and endocrine organs during treatment and after discontinuation.
- Monitor thyroid function and blood glucose at baseline and periodically; assess adrenal and pituitary function when clinically indicated.
- Review liver biochemistry, renal function, electrolytes and blood counts as clinically appropriate.
- Evaluate cardiac or cardiopulmonary symptoms urgently for myocarditis, including possible overlap with myositis or myasthenia gravis.
- Observe for infusion reactions and record the product name and batch number for biological traceability.
Clinical pharmacology
Both components are human IgG4 monoclonal antibodies. Nivolumab blocks PD-1 interaction with PD-L1 and PD-L2; relatlimab blocks LAG-3 signalling. They are expected to undergo protein catabolism rather than CYP metabolism.
Formulation and product differences
- The selected product is a fixed-combination, preservative-free concentrate in a single-use vial for intravenous infusion.
- It may be administered undiluted or diluted with compatible sodium chloride or glucose infusion fluid.
- Do not mix it with other medicines or administer other medicines through the same infusion line.
nivolumab + relatlimab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 240 mg + 80 mg
nivolumab + relatlimab interactions
Formal interaction studies have not been conducted. Clinically important CYP-mediated pharmacokinetic interactions are not expected, but the cancer team should review all prescribed, over-the-counter and complementary products.
Systemic corticosteroids and other immunosuppressants
Baseline use should generally be avoided because it may interfere with checkpoint-inhibitor activity, although these medicines are commonly used after treatment starts to manage immune-related reactions.
Medicines metabolised by CYP enzymes
A direct pharmacokinetic interaction is not expected because these antibodies are not metabolised through CYP pathways and do not significantly alter them.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.